PROTECT YOUR LIVER FROM HEPATITIS

Amita Tilak, R. N. Thakur, Sudhir Singh Gangwar, Ranjana Sharma

Abstract


Hepatitis  virus infection is a major  health problem around theworld and 30% of the world's population display serological indication of current or past infection of hepatitis. Hepatitis B virus is a somewhat double-stranded DNA virus through several serological indicators like  HBsAg and anti-HBs, HBeAg and anti-HBe, and anti-HBc IgM and IgG. HBsAg and anti-HBs, HBeAg and anti-HBe, and anti-HBc IgM and IgG. Hepatitis is an inflammation disease that occour  in our  liver. It may be produced by drugs, alcohol, or convinced medical conditions. But in maximum cases, it's caused by a virus. This is documented as viral hepatitis, and the most general forms are hepatitis A, B, and C. Hepatitis signals to an inflammation of the liver cells that damage to the liver. There are varied types and causes, but the suggestions can be similar Antiviral actions for chronic hepatitis B consist of interferon (IFN) therapy and nucleoside equivalentslike (lamivudine, adefovir, and entecavir therapy. Handling strategies are categoricalconstructed on the patient age, viral load, presence/absence of HBeAg, and development of fibrosis.


Keywords


Hepatitis B, DNA virus, inflammation, IgM and IgG, viral hepatitis

Full Text:

7-10

References


http://clinic.cancercarefoundationofindia.org/liver.html?gclid=CjwKCAiAr_TQBRB5EiwAC_QCq21kM20zh32S2qGnS6pKrcUdtMaAZZmDT1iwo0jvp_1aMcSfF0dQBoCm28QAvD_BwE

https://www.webmd.com/hepatitis/understanding-hepatitis-treatment#2

Substance Abuse and Mental Health Services Administration. Results from the 2006 National Survey on Drug Use and Health: National Findings (Office of Applied Studies, NSDUH Series H-32, DHHS Publication No. SMA 07-4293). Rockville, MD. 2007

Humeniuk R, Ali R. Validation of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) and pilot brief intervention [electronic resource]: a technical

https://www.healthline.com/health/hepatitis

https://www.webmd.com/hepatitis/default.htm

Edlin BR. Hepatitis C screening: getting it right. Hepatology. Apr 2013;57(4):1644-1650.

https://www.medicalnewstoday.com/articles/145869.php

https://www.medicinenet.com/viral_hepatitis/article.htm

http://clinic.healthmailer.info/liver.html?gclid=CjwKCAiAr_TQBRB5EiwAC_QCq_NJ7VHKmtxeZLywZ-t2rvUuqp0C_8vnApM_IJ28a7SrWql6BB8RWhoC4RYQAvD_BwE

Alter HJ, Seeff LB. Transfusion-associated hepatitis. In: Zuckerman AJ, Thomas HC, eds. Viral hepatitis scientific basis and clinical management. 467. Edinburgh: Churchill Livingstone, 1993.

https://www.webmd.boots.com/digestive-disorders/digestive-diseases-hepatitis

Alter HJ. Transfusion-associated non-A, non-B he patitis: The first decade. In: Zuckerman AJ, ed. Vira hepatitis and liver disease. 537. New York: Alan R Liss, 1988.

Dusheiko G, Schmilovitz-Weiss H, Brown D, McOmish F, Yap P-L, Sherlok S, Mclntyre N, Simmonds P. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 1994;19:13.

Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep. Oct 16 1998;47(RR-19):1-39.

Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156.

http://www.who.int/mediacentre/factsheets/fs328/en/

. Matsumoto A, Tanaka E, Suzuki T, Ogata H, Kiyosawa K. Viral and host factors that contribute to efficacy of interferon-α2atherapy in patients with chronic hepatitis C. Dig Dis Sci 1994;39:1273.

https://en.wikipedia.org/wiki/Hepatitis_B_virus

Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and geno types. Sem Liver Dis 1995;15:41.

Silini E, Bono F, Cividini A, Cerino A, Bruno S, Rossi S, Belloni G, Brugnetti B, Civardi E, Salvaneschi L, Mondelli MU. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology 1995;21:285.

Civeira MP, Prieto J. Early predictors of response to treatment in patients with chronic hepatitis C. J Hepatol 1999;31:237-43

Moyer VA. Screening for Hepatitis C Virus Infection in Adults: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. Jun 25 2013.

https://www.hepmag.com/basics/hepatitis-b-basics/hepatitis-b-treatment

Kobayashi Y, Watanabe S, Konishi M. Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with inter feron-β. Hepatology 1993;18:1319.

https://en.wikipedia.org/wiki/List_of_antiviral_drugs Report of phase II findings of the WHO ASSIST Project. Geneva, Switzerland: World Health Organization; 2006.

Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, Hashimoto M, Iwasaki S, Kobayashi M, Hiromitsu K. Factors predictive of response to inter-feron-α therapy in hepatitis C virus infection. Hepatology 1994;19:1088.




DOI: http://dx.doi.org/10.24018/10.24018/iijmps.2018.v1i1.22

DOI (7-10): http://dx.doi.org/10.24018/10.24018/iijmps.2018.v1i1.22

Refbacks

  • There are currently no refbacks.